Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  HeartWare International Inc    HTWR

News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

HeartWare : Roy Jacobs & Associates Commences Investigation on Behalf of HeartWare International, Inc. Shareholders - HTWR

02/04/2016 | 01:04pm US/Eastern

By a News Reporter-Staff News Editor at Clinical Trials Week -- Roy Jacobs & Associates announces that it has commenced an investigation as to whether the Board of Directors of HeartWare International, Inc. ("HTWR" or the "Company") violated their fiduciary duty and, if so, what legal action can be taken to protect shareholders' and the Company's interests (see also Roy Jacobs & Associates).

For further information, please call Roy L. Jacobs toll-free at 1-888-884-4490 or E-mail at rjacobs@jacobsclasslaw.com.

HeartWare is a medical device company that develops and manufactures miniature heart pumps that are implanted into the patient's body. It has been alleged that after the U.S. Food and Drug Administration ("FDA") issued a Warning Letter to the Company identifying numerous manufacturing and other regulatory failures at the Company's sole manufacturing facility, various officers and directors misled investors, in violation of their fiduciary duties, when they assured investors that the Company was addressing problems with HeartWare's manufacturing and other regulatory failures. The officers and directors repeatedly told investors that the items the FDA noted in its Warning Letter posed no risk to the clinical trials or timely approval of its new MVAD pump.

On September 9, 2015, HeartWare disclosed that it was halting enrollment in the MVAD trial because of a manufacturing problem with the device. On October 12, 2015, HeartWare disclosed that patients in the MVAD trial had suffered adverse events, and that the trial would be further delayed. Finally, on January 11, 2016, the Company revealed that problems with MVAD caused serious adverse events in nearly half of the patients so far implanted with the device, and that the trial would be delayed indefinitely.

In response to each of these disclosures, the price of HeartWare's common stock declined significantly. In total, HeartWare's common stock fell dramatically from its recent high to close at $34 per share on January 25, 2016.

If you are a long term holder of HeartWare shares and intend to hold your shares and wish to discuss potentially joining in an action to protect your rights, or have any questions concerning this notice, please contact Roy Jacobs. Mr. Jacobs will personally speak with you at no cost or obligation. View source version on businesswire.com: http://www.businesswire.com/news/home/20160126006269/en/

Keywords for this news article include: Legal Issues, Roy Jacobs & Associates.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

(c) 2016 NewsRx LLC, source Health Newsletters

React to this article
02/04 HEARTWARE : Roy Jacobs & Associates Commences Investigation on Behalf of HeartWa..
02/04 HEARTWARE : Glancy Prongay & Murray LLP Announces the Filing of a Securities Cla..
02/04 HEARTWARE : Harwood Feffer LLP Announces Investigation of HeartWare Internationa..
02/03 HEARTWARE : Presentation At The Leerink Partners 5th Annual Global Healthcare Co..
02/01 HEARTWARE : HTWR INVESTORS ALERT: Lieff Cabraser Announces Securities Class Acti..
01/29 HEARTWARE : DEADLINE ALERT: Goldberg Law PC Announces Securities Class Action La..
01/29 HEARTWARE : HTWR) Misled Shareholders According to a Recently Filed Class Action..
01/29 HEARTWARE : The Law Offices of Howard G. Smith Announces the Filing of a Securit..
01/28 HEARTWARE : Entry into a Material Definitive Agreement, Financial Statements and..
01/28 HEARTWARE : Termination of a Material Definitive Agreement, Financial Statements..
News chart
Full-screen chart
Income Statement Evolution
More Financials